BAM Logo

SARS-CoV-2 Proficiency Testing Scheme

EPTIS factsheet 769005 | Last revision 2022-05-04 | URL: https://www.eptis.bam.de/pts769005 https://www.eptis.bam.de/pts769005

PT provider
PT provider LGC AXIO Proficiency Testing LGC AXIO Proficiency Testing
Based in United Kingdom
Remarks The primary aim of the Clinical Laboratory proficiency testing scheme (CLS) is to enable laboratories performing analysis of clinical samples to monitor their performance and compare it with that of their peers. The CLS scheme also aims to provide information to participants on technical issues and methodologies relating to Clinical Laboratory Science. The CLS scheme year operates from January to December. Further information about CLS, including test material availability, round despatch dates and reporting deadlines, are available on the current CLS application form. The operation of the scheme is supported by an Advisory Group consisting of experts in the field of Clinical Laboratory Science and proficiency testing. The scheme reports on the performance of U.K. participants to the National Quality Assurance Advisory Panels for Chemical Pathology and for Medical Microbiology.
Product groups Human test material
Testing fields Biology
Medical analysis
Technical details
Test item Tested property Testing method
SARS-CoV-2 (Serological)- 3 x 0.75 ml samples for detection for the SARS-CoV-2 antibodies -NEW 2020 SARS-CoV-2 IgA, IgG, IgM, Total antibodies The samples are suitable for antibody detection methods
The samples are derived from naturally occurring material collected via apheresis from patients that have recovered from COVID-19.
Qualitative (presence/absence)
SARS-CoV-2 (Molecular)- 2 x 1.5ml samples for SARS-CoV-2 virus -NEW 2020 SARS-CoV-2 virus The samples are suitable for methods that target the CDC/WHO consensus genomic RNA sequences
The samples contain the whole genome.
Qualitative (presence/absence)
SARS-CoV-2 antigen - 3 x swab based samples (A, B, and C). Non-infectious simulated patient nasopharyngeal samples containing the SARS-CoV-2 nucleocapsid protein. SARS-CoV-2 virus Qualitative (presence/absence)
SARS-CoV-2 (Molecular)- 2 x swab based samples. Non-infectious simulated nasopharyngeal samples containing the SARS-CoV-2 genome. The samples contain the whole genome SARS-CoV-2 virus - The samples contain the whole genome Qualitative (presence/absence)
SARS-CoV-2 Quality Control Pack SARS-CoV-2 virus - The samples contain the whole genome Qualitative (presence/absence)
Aims of the PT scheme
Target group of participants Clinical laboratories, other
Linked to specific legislation / standards
Additional, subsidiary aims validation of testing methods
Number of participants
Accredited or otherwise reviewed by a 3rd party

Accredited by A2LA, UKAS, ILAV-MRA on the basis of ISO/IEC 17043:2010 for part of the parameters

Operation is commissioned / requested by
Fees and frequency
Participation fee Fees vary according to selection from available groups.
Regularly operated Yes (12 rounds per year)
Year of first operation 2018
Contact details of the PT provider
Provider Contact person
LGC AXIO Proficiency Testing
1 Chamberhall Business Park, Chamberhall Green
BL9 0AP Bury, Greater Manchester
United Kingdom

Phone: +44 (0)161 762 2500
Fax: +44 (0)161 762 2501
Web: https://www.lgcstandards.com/GB/en/Proficiency-Testing/cat/244597 https://www.lgcstandards.com/GB/en/Proficiency-Testing/cat/244597
Mrs Nicola Armstrong
Phone: +44 (0)161 762 2500
Email: axiopt@lgcgroup.com axiopt@lgcgroup.com
If you find any mistakes please contact the responsible EPTIS coordinator in United Kingdom, Mr Savvas Xystouris. Mr Savvas Xystouris.
Any questions or problems? Please contact us at eptis@bam.de.
Application version: 1.23-SNAPSHOT.20230502124635-7925ae379a631fc1ececff45d2921c8db38877d5